These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 19710098)
1. Enhanced induction of a histamine-forming enzyme, histidine decarboxylase, in mice primed with NOD1 or NOD2 ligand in response to various Toll-like receptor agonists. Funayama H; Huang L; Asada Y; Endo Y; Takada H Innate Immun; 2010 Aug; 16(4):265-72. PubMed ID: 19710098 [TBL] [Abstract][Full Text] [Related]
2. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Tada H; Aiba S; Shibata K; Ohteki T; Takada H Infect Immun; 2005 Dec; 73(12):7967-76. PubMed ID: 16299289 [TBL] [Abstract][Full Text] [Related]
3. Analgesic effects of chemically synthesized NOD1 and NOD2 agonists in mice. Sato T; Shikama Y; Shimauchi H; Endo Y; Takada H Innate Immun; 2011 Feb; 17(1):54-9. PubMed ID: 20083500 [TBL] [Abstract][Full Text] [Related]
4. Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Uehara A; Yang S; Fujimoto Y; Fukase K; Kusumoto S; Shibata K; Sugawara S; Takada H Cell Microbiol; 2005 Jan; 7(1):53-61. PubMed ID: 15617523 [TBL] [Abstract][Full Text] [Related]
5. RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs. Park JH; Kim YG; McDonald C; Kanneganti TD; Hasegawa M; Body-Malapel M; Inohara N; Núñez G J Immunol; 2007 Feb; 178(4):2380-6. PubMed ID: 17277144 [TBL] [Abstract][Full Text] [Related]
6. Nod2 and Rip2 contribute to innate immune responses in mouse neutrophils. Jeong YJ; Kang MJ; Lee SJ; Kim CH; Kim JC; Kim TH; Kim DJ; Kim D; Núñez G; Park JH Immunology; 2014 Oct; 143(2):269-76. PubMed ID: 24766550 [TBL] [Abstract][Full Text] [Related]
7. A vitamin D3 analog augmented interleukin-8 production by human monocytic cells in response to various microbe-related synthetic ligands, especially NOD2 agonistic muramyldipeptide. Ikeuchi T; Nakamura T; Fukumoto S; Takada H Int Immunopharmacol; 2013 Jan; 15(1):15-22. PubMed ID: 23159604 [TBL] [Abstract][Full Text] [Related]
8. Synergistic effects of NOD1 or NOD2 and TLR4 activation on mouse sickness behavior in relation to immune and brain activity markers. Farzi A; Reichmann F; Meinitzer A; Mayerhofer R; Jain P; Hassan AM; Fröhlich EE; Wagner K; Painsipp E; Rinner B; Holzer P Brain Behav Immun; 2015 Feb; 44():106-20. PubMed ID: 25218901 [TBL] [Abstract][Full Text] [Related]
9. Expression of TRAF6 and pro-inflammatory cytokines through activation of TLR2, TLR4, NOD1, and NOD2 in human periodontal ligament fibroblasts. Tang L; Zhou XD; Wang Q; Zhang L; Wang Y; Li XY; Huang DM Arch Oral Biol; 2011 Oct; 56(10):1064-72. PubMed ID: 21457942 [TBL] [Abstract][Full Text] [Related]
10. Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Uehara A; Fujimoto Y; Fukase K; Takada H Mol Immunol; 2007 May; 44(12):3100-11. PubMed ID: 17403538 [TBL] [Abstract][Full Text] [Related]
11. Enhancement of TLR-mediated innate immune responses by peptidoglycans through NOD signaling. Takada H; Uehara A Curr Pharm Des; 2006; 12(32):4163-72. PubMed ID: 17100619 [TBL] [Abstract][Full Text] [Related]
12. NOD1 and NOD2 stimulation triggers innate immune responses of human periodontal ligament cells. Jeon DI; Park SR; Ahn MY; Ahn SG; Park JH; Yoon JH Int J Mol Med; 2012 Apr; 29(4):699-703. PubMed ID: 22218461 [TBL] [Abstract][Full Text] [Related]
13. Chemically synthesized pathogen-associated molecular patterns increase the expression of peptidoglycan recognition proteins via toll-like receptors, NOD1 and NOD2 in human oral epithelial cells. Uehara A; Sugawara Y; Kurata S; Fujimoto Y; Fukase K; Kusumoto S; Satta Y; Sasano T; Sugawara S; Takada H Cell Microbiol; 2005 May; 7(5):675-86. PubMed ID: 15839897 [TBL] [Abstract][Full Text] [Related]
14. Selective NOD1 agonists cause shock and organ injury/dysfunction in vivo. Cartwright N; Murch O; McMaster SK; Paul-Clark MJ; van Heel DA; Ryffel B; Quesniaux VF; Evans TW; Thiemermann C; Mitchell JA Am J Respir Crit Care Med; 2007 Mar; 175(6):595-603. PubMed ID: 17234906 [TBL] [Abstract][Full Text] [Related]
15. Phenotypic Differences in Primary Murine Microglia Treated with NOD1, NOD2, and NOD1/2 Agonists. Wasmuth S; Jalilvand TV; Laffer B; Busch M; Bauer D; Langmann T; Thanos S; Kasper M; Heiligenhaus A J Mol Neurosci; 2020 Apr; 70(4):600-609. PubMed ID: 31907866 [TBL] [Abstract][Full Text] [Related]
16. Roles of TLR2, TLR4, NOD2, and NOD1 in pulp fibroblasts. Hirao K; Yumoto H; Takahashi K; Mukai K; Nakanishi T; Matsuo T J Dent Res; 2009 Aug; 88(8):762-7. PubMed ID: 19734466 [TBL] [Abstract][Full Text] [Related]
17. Nod1 and Nod2 induce CCL5/RANTES through the NF-kappaB pathway. Werts C; le Bourhis L; Liu J; Magalhaes JG; Carneiro LA; Fritz JH; Stockinger S; Balloy V; Chignard M; Decker T; Philpott DJ; Ma X; Girardin SE Eur J Immunol; 2007 Sep; 37(9):2499-508. PubMed ID: 17705131 [TBL] [Abstract][Full Text] [Related]
18. NOD-like receptors and RIG-I-like receptors in human eosinophils: activation by NOD1 and NOD2 agonists. Kvarnhammar AM; Petterson T; Cardell LO Immunology; 2011 Nov; 134(3):314-25. PubMed ID: 21978001 [TBL] [Abstract][Full Text] [Related]
19. Antibodies to proteinase 3 prime human monocytic cells via protease-activated receptor-2 and NF-kappaB for Toll-like receptor- and NOD-dependent activation. Uehara A; Iwashiro A; Sato T; Yokota S; Takada H Mol Immunol; 2007 Jul; 44(14):3552-62. PubMed ID: 17452051 [TBL] [Abstract][Full Text] [Related]
20. Enhancement of endotoxin activity by muramyldipeptide. Takada H; Yokoyama S; Yang S J Endotoxin Res; 2002; 8(5):337-42. PubMed ID: 12537692 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]